Jamaica Observer: Lowe and Team Granted Licence for Further Development of Prostate Cancer Drug
Thursday, December 20, 2018
A United States-based corporation founded in 2015 by Jamaican scientist Dr Henry Lowe has been granted an exclusive licence by the University of Maryland, Baltimore (UMB) for the development of Galeterone, a molecule with the potential to inhibit prostate cancer growth in patients with castration-resistant prostate cancer.
The development was announced by UMB's Office of Technology Transfer earlier this week.
“My research team and I are particularly grateful that the University of Maryland, Baltimore has seen it fit to trust us to take such an important drug forward. We expect to satisfy and exceed the expectations of the president of the university and our many supporters,” Dr Lowe is quoted in a news release from his corporation, Educational & Scientific, LLC (ESL).
Click here to read the rest of the story via the Jamaica Observer.